Trial Profile
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 15 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2023 Planned number of patients changed from 120 to 240.
- 02 Nov 2022 Planned End Date changed from 1 Jul 2028 to 1 Jun 2028.